| CRSP | 8-K | bearish | 5/10 | CRISPR Therapeutics reported Q1 2026 EPS of -$1.28, missing consensus of -$1.14 by 12.3%. Total revenue of $1.5M was up | May 4, 2026 |
| TWST | 8-K | bullish | 7/10 | Twist Bioscience reported fiscal Q2 2026 revenue of $110.7M, a 19% YoY increase and above the prior quarter's $103.7M, w | May 4, 2026 |
| NEO | 8-K | bullish | 6/10 | NeoGenomics reported Q1 2026 revenue of $187M (+11% YoY), beating consensus of $184.5M, and raised full-year revenue gui | Apr 28, 2026 |
| NTLA | 8-K | bullish | 8/10 | Intellia Therapeutics announced positive Phase 3 topline data for its investigational CRISPR-based therapy lonvo-z in he | Apr 27, 2026 |
| DNABW | 8-K | neutral | 5/10 | Ginkgo Bioworks completed the disposition of its Biosecurity segment to Tower Biosecurity, Inc. in exchange for a 20% eq | Apr 7, 2026 |
| EDIT | 8-K | neutral | 3/10 | Editas Medicine dismissed Ernst & Young as its auditor and appointed PricewaterhouseCoopers (PwC) effective April 1, 202 | Apr 7, 2026 |
| ILMN | 8-K | neutral | 3/10 | Illumina announced that three board members—Drs. Frances Arnold, Robert S. Epstein, and Gary S. Guthart—will retire at t | Apr 2, 2026 |
| BEAM | 8-K | neutral | 4/10 | Beam Therapeutics Inc. (BEAM) and Bio Palette Co., Ltd. mutually terminated their 2019 License Agreement due to Bio Pale | Mar 5, 2026 |
| PACB | 8-K | neutral | 3/10 | Pacific Biosciences appointed Christopher Gibson, Ph.D., to its Board of Directors and Science and Technology Committee, | Mar 5, 2026 |
| NTLA | 8-K | mixed | 6/10 | Intellia Therapeutics reported its Q4 and full-year 2025 financial results, highlighting a reduction in net loss to $95. | Feb 26, 2026 |
| RXRX | 8-K | bullish | 8/10 | Recursion reported strong financial results for Q4 and full year 2025, highlighted by a 689% year-over-year increase in | Feb 25, 2026 |
